Sandrine Théoleyre

1.8k total citations · 1 hit paper
25 papers, 1.4k citations indexed

About

Sandrine Théoleyre is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Sandrine Théoleyre has authored 25 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 14 papers in Cancer Research and 12 papers in Oncology. Recurrent topics in Sandrine Théoleyre's work include Cancer Genomics and Diagnostics (9 papers), Bone Metabolism and Diseases (7 papers) and Bone health and treatments (6 papers). Sandrine Théoleyre is often cited by papers focused on Cancer Genomics and Diagnostics (9 papers), Bone Metabolism and Diseases (7 papers) and Bone health and treatments (6 papers). Sandrine Théoleyre collaborates with scholars based in France, United States and Switzerland. Sandrine Théoleyre's co-authors include Dominique Heymann, Françoise Rédiní, Yohann Wittrant, Yannick Fortun, Steeve Kwan Tat, Marc G. Denis, Frédéric Blanchard, Audrey Vallée, M. Padrines and Séverine Couillaud and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Biochemical and Biophysical Research Communications.

In The Last Decade

Sandrine Théoleyre

25 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling

2004 518 citations Sandrine Théoleyre, Yohann Wittrant et al. Cytokine & Growth Factor Reviews profile →

Peers

Countries citing papers authored by Sandrine Théoleyre

Since Specialization

Citations

This map shows the geographic impact of Sandrine Théoleyre's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandrine Théoleyre with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandrine Théoleyre more than expected).

Fields of papers citing papers by Sandrine Théoleyre

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandrine Théoleyre. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandrine Théoleyre. The network helps show where Sandrine Théoleyre may publish in the future.

Co-authorship network of co-authors of Sandrine Théoleyre

This figure shows the co-authorship network connecting the top 25 collaborators of Sandrine Théoleyre. A scholar is included among the top collaborators of Sandrine Théoleyre based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandrine Théoleyre. Sandrine Théoleyre is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	MEM: An Algorithm for the Reliable Detection of Microsatellite Instability (MSI) on a Small NGS Panel in Colorectal Cancer 2021 ·Cancers ·Guillaume Herbreteau, Fabrice Airaud, (unknown), Audrey Vallée, Stéphane Bezieau, Sandrine Théoleyre, Hélène Blons, Simon Garinet, Marc G. Denis	5
2	Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay 2019 ·PLoS ONE ·Audrey Vallée, (unknown), Guillaume Herbreteau, Sandrine Théoleyre, Céline Bossard, Marc G. Denis	17
3	Circulating tumour DNA: analytical aspects and clinical applications for metastatic melanoma patients 2017 ·Annales de biologie clinique ·Guillaume Herbreteau, Audrey Vallée, Anne‐Chantal Knol, Sandrine Théoleyre, G. Quéreux, Amir Khammari, Brigitte Dréno, Marc G. Denis	10
4	Efficient treatment of a metastatic melanoma patient with a combination of BRAF and MEK inhibitors based on circulating tumor DNA analysis: a case report 2017 ·BMC Research Notes ·G. Quéreux, Guillaume Herbreteau, Anne‐Chantal Knol, Audrey Vallée, Amir Khammari, Sandrine Théoleyre, M. Saint‐Jean, Brigitte Dréno, Marc G. Denis	7
5	EGFR T790M resistance mutation in non small-cell lung carcinoma 2015 ·Clinica Chimica Acta ·Marc G. Denis, Audrey Vallée, Sandrine Théoleyre	62
6	La neutrophil gelatinase-associated lipocalin, ou LCN 2, facteur d’agressivité dans le carcinome rénal à cellules claires (CRCC) 2011 ·Progrès en Urologie ·Christophe Perrin, (unknown), Florence Jouan, Nicolas Collet, Sandrine Théoleyre, Julien Edeline, (unknown), Brigitte Laguerre, (unknown), N. Costedoat‐Chalumeau, Cécile Vigneau	12
7	Loss of expression of TIMP3 in clear cell renal cell carcinoma 2010 ·European Journal of Cancer ·Damien Masson, (unknown), Patricia Fergelot, Florence Jouan, Stéphanie Mottier, Sandrine Théoleyre, Kalyane Bach‐Ngohou, Jean‐Jacques Patard, Marc G. Denis	44
8	Efficient detection of EGFR alterations in lung adenocarcinomas. 2010 ·Journal of Clinical Oncology ·(unknown), Sandrine Théoleyre, (unknown), (unknown), Sylvie Caulet-Maugendre, (unknown), (unknown), H. Léna, Christine Sagan, Jaafar Bennouna	3
9	HtrA3 is regulated by 15-deoxy-Δ12,14-prostaglandin J2 independently of PPARγ in clear cell renal cell carcinomas 2009 ·Biochemical and Biophysical Research Communications ·Sandrine Théoleyre, Stéphanie Mottier, Damien Masson, Marc G. Denis	8
10	KLF4‐dependent, PPARγ‐induced expression of GPA33 in colon cancer cell lines 2009 ·International Journal of Cancer ·Julie Rageul, Stéphanie Mottier, Anne Jarry, Yatrik M. Shah, Sandrine Théoleyre, Damien Masson, Frank J. Gonzalez, Christian Laboisse, Marc G. Denis	40
11	Cooperative binding of TIA-1 and U1 snRNP in K-SAM exon splicing activation 2007 ·Biochemical and Biophysical Research Communications ·Marie-Claude Gesnel, Sandrine Théoleyre, Fabienne Del Gatto–Konczak, Richard Breathnach	10
12	Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: Role in the interactions with receptor activator of nuclear factor κB ligand (RANKL) and RANK 2006 ·Biochemical and Biophysical Research Communications ·Sandrine Théoleyre, (unknown), Patricia Vusio, Frédéric Blanchard, (unknown), Sylvie Ricard‐Blum, Yannick Fortun, M. Padrines, Françoise Rédiní, Dominique Heymann	79
13	OPG/membranous–RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation 2006 ·Bone ·Steeve Kwan Tat, Marc Padrines, Sandrine Théoleyre, (unknown), Dominique Heymann, Françoise Rédiní, Yannick Fortun	56
14	Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma 2005 ·BMC Cancer ·Sandrine Théoleyre, (unknown), (unknown), Norbert Passuti, F. Gouin, Françoise Rédiní, Dominique Heymann	59
15	The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling breakdown → 2004 ·Cytokine & Growth Factor Reviews ·Sandrine Théoleyre, Yohann Wittrant, Steeve Kwan Tat, Yannick Fortun, Françoise Rédiní, Dominique Heymann	518
16	RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis 2004 ·Biochimica et Biophysica Acta (BBA) - Reviews on Cancer ·Yohann Wittrant, Sandrine Théoleyre, (unknown), M. Padrines, Frédéric Blanchard, Dominique Heymann, Françoise Rédiní	191
17	Cellular activity and signaling induced by osteoprotegerin in osteoclasts: involvement of receptor activator of nuclear factor κB ligand and MAPK 2003 ·Biochimica et Biophysica Acta (BBA) - Molecular Cell Research ·Sandrine Théoleyre, Yohann Wittrant, Séverine Couillaud, Patricia Vusio, Martine Berreur, Colin R. Dunstan, Frédéric Blanchard, Françoise Rédiní, Dominique Heymann	41
18	Regulation of osteoclast protease expression by RANKL 2003 ·Biochemical and Biophysical Research Communications ·Yohann Wittrant, Sandrine Théoleyre, Séverine Couillaud, Colin R. Dunstan, Dominique Heymann, Françoise Rédiní	46
19	Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-kB ligand and osteoprotegerin biological activities 2003 ·Experimental Cell Research ·Yohann Wittrant, Sandrine Théoleyre, Séverine Couillaud, Colin R. Dunstan, Dominique Heymann, Françoise Rédiní	46
20	Osteoprotegerin differentially regulates protease expression in osteoclast cultures 2002 ·Biochemical and Biophysical Research Communications ·Yohann Wittrant, Séverine Couillaud, Sandrine Théoleyre, Colin R. Dunstan, Dominique Heymann, Françoise Rédiní	52

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact